Bayer Schering Pharma granted orphan drug status for CF treatment

11 March 2010 00:00 in Pharmaceutical Company Product News


Bayer Schering Pharma has received orphan drug designation from the Food and Drug Administration (FDA) for a treatment for chronic pulmonary infections related to cystic fibrosis (CF).

The ciprofloxacin dry powder inhaler (DPI) treatment, which is formulated using Novartis' PulmoSphere technology and administered using an inhaler, was granted this classification following positive clinical trial results.

This follows a similar decision from the European Medicines Agency and guarantees the company exclusive rights to market its treatment for the rare condition.

Dr Jean-Philippe Milon, head of the general medicine global business unit at Bayer Schering Pharma, described the news as a positive step for sufferers of the disease.

He said: "With ciprofloxacin DPI, we are investigating a promising and convenient treatment option for CF patients worldwide."

Earlier this week, the company commenced a phase III clinical trial of its contrast agent Gadovist for application in magnetic resonance imaging of breast cancer patients.

Other news stories from 11/03/2010

• Bayer Schering Pharma granted orphan drug status for CF treatment
• AstraZeneca agrees deal with Torrent over generics portfolio
• Takeda makes milestone payment to Affymax over Hematide development
• Allergan receives approval for Botox in muscle stiffness treatment
• Porter Novelli appoints EMEA healthcare regional head
• Abbott receives FDA approval for intraocular lens
• Sartorius reports earnings increase in 2010
• Life Technologies system used in groundbreaking research
• Advanced Medical Solutions reports rising revenues in 2009
• Bausch and Lomb appoints vision care executive
• AstraTech unveils new OsseoSpeed TX implant

Related news

• Bayer HealthCare's rivaroxaban shows efficacy in stroke prevention
• Bayer establishes new medical devices materials branding
• Bayer Schering Pharma granted orphan drug status for CF treatment
• Bayer Schering Pharma launches trial of breast cancer treatment
• Bayer launches USB-based blood glucose meter

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Adfero News Agency

Feedback | News Archive | Browse News | Hotels | Links | Browse Jobs | Legal Notice | Privacy Policy

© Copyright 2013 Zenopa Ltd